Cargando…

Pre-clinical development of the human CD40 agonistic antibody ADC-1013

Detalles Bibliográficos
Autores principales:	Norlén, Per, Veitonmäki, Niina, Smith, Karin Enell, Tötterman, Thomas H, Mangsbo, Sara M, Furebring, Christina, Ellmark, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649480/ http://dx.doi.org/10.1186/2051-1426-3-S2-P185

Ejemplares similares

ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
por: Mangsbo, Sara M, et al.
Publicado: (2013)

The human CD40 agonistic antibody ADC-1013 generates immune mediated anti-tumor effects in syngeneic tumor models in hCD40 transgenic mice
por: Mangsbo, Sara M, et al.
Publicado: (2014)

Kick-starting the cancer-immunity cycle by targeting CD40
por: Ellmark, P, et al.
Publicado: (2015)

The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
por: Deronic, Adnan, et al.
Publicado: (2021)

Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
por: Ellmark, Peter, et al.
Publicado: (2016)

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
por: Kvarnhammar, Anne Månsson, et al.
Publicado: (2019)

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer
por: Sandin, Linda C, et al.
Publicado: (2014)

Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
por: Andersson, Hampus, et al.
Publicado: (2023)

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo
por: Sandin, Linda C, et al.
Publicado: (2014)

Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment
por: van Hooren, Luuk, et al.
Publicado: (2016)

Synergistic effects of agonistic costimulatory antibodies adsorbed to amphiphilic poly(γ-glutamic acid) nanoparticles
por: Freiburghaus, Catja, et al.
Publicado: (2013)

Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
por: Schiza, A., et al.
Publicado: (2017)

Agonistic CD40 Antibodies in Cancer Treatment
por: Djureinovic, Dijana, et al.
Publicado: (2021)

Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients
por: Loskog, Angelica, et al.
Publicado: (2016)

Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
por: Salomon, Ran, et al.
Publicado: (2022)

CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches
por: Argiriadi, Maria A., et al.
Publicado: (2019)

Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients
por: Irenaeus, Sandra, et al.
Publicado: (2017)

Le synchrotron injecteur accélère 1013 ppi
Publicado: (1974)

macOS support essentials 10.13
por: Dreyer, Arek, et al.
Publicado: (2018)

1013 ejercicios y juegos aplicados al balonmano
por: Lasierra, Gerard
Publicado: (1992)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
por: Nelson, Michelle H., et al.
Publicado: (2023)

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
por: Hägerbrand, Karin, et al.
Publicado: (2022)

Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies
por: Li, Da-Ke, et al.
Publicado: (2020)

Characterization of a Broadly Reactive Anti-CD40 Agonistic Monoclonal Antibody for Potential Use as an Adjuvant
por: Martin, Cameron, et al.
Publicado: (2017)

1013. Enhanced Oral Health Care Services for PLWHA - Midlands Region, South Carolina
por: Baello, Christina M, et al.
Publicado: (2020)

Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
por: van Hooren, Luuk, et al.
Publicado: (2021)

CD40 agonist-induced IL-12p40 potentiates hepatotoxicity
por: Bonnans, Caroline, et al.
Publicado: (2020)

Partita g-moll für Viola solo, nach BWV 1013
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1992)

Can one 1013 proton burst melt the ps vacuum chamber?
por: Steinbach, C
Publicado: (1973)

HCV genotypes among 1013 Saudi nationals: a multicenter study
por: Al Traif, Ibrahim, et al.
Publicado: (2013)

1013. Electronic Assessment of Empiric Antibiotic Prescribing Using Diagnosis Codes
por: Dodds Ashley, Elizabeth, et al.
Publicado: (2019)

Introduction: Medicare Section 1013 and AHRQ's Effective Health Care Program
por: Chao, Schumarry H., et al.
Publicado: (2007)

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
por: Georganaki, Maria, et al.
Publicado: (2020)

Concepts for agonistic targeting of CD40 in immuno-oncology
por: Richards, David M., et al.
Publicado: (2019)

1.013 ejercicios y juegos polideportivos : deportes de cooperación/oposición : baloncesto, balonmano, fútbol, hockey, rugby, voleibol, waterpolo /
por: Ticó Camí, Jordi
Publicado: (2000)

The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities
por: Bjorck, Pia, et al.
Publicado: (2015)

Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
por: Baumann, Daniel, et al.
Publicado: (2020)

Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy
por: Zhang, Yajun, et al.
Publicado: (2021)

CD40 Agonist Monoclonal Antibody-Mediated Hepatitis in TNF-Receptor 1 Gene Knockout Mice
por: Raabe, Oksana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_36ipc72igd2k9fta5n0rn7b3k4